Samsung Bioepis signs Teva biosimilar deal worth up to USD 420 million

Bitget2026/11/03 08:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Samsung EPIS Holdings subsidiary Samsung Bioepis signed a deal worth up to USD 420 million with Teva on November 2, 2026.
Teva will sell FDA-approved SB2, a Remicade biosimilar, and SB4, an Enbrel biosimilar, in the U.S.
Samsung Bioepis will handle development, manufacturing and supply; the partners will share commercialization profits under the agreement.
Upfront payments total up to USD 75 million: USD 50 million within 30 calendar days of effectiveness; USD 25 million upon conditions.
Additional payments include up to USD 75 million in launch milestones and USD 270 million in sales milestones, subject to contractual targets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung EPIS Holdings Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261103800583), on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Samsung Bioepis signs Teva biosimilar deal worth up to USD 420 million

You may also like

Crypto prices